Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SynAct Pharma AB ( (SE:SYNACT) ) has shared an announcement.
SynAct Pharma AB announced it received SEK 17.7 million following the conversion of 1,000,000 warrants by Heights Capital Management, Inc. This financial boost strengthens SynAct’s financial position, extending its operational runway into 2027 and supporting its development opportunities and discussions with potential partners.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm. It focuses on resolving inflammation through the selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation.
Average Trading Volume: 222,948
Current Market Cap: SEK1.09B
For a thorough assessment of SYNACT stock, go to TipRanks’ Stock Analysis page.